Mesoblast Ltd
Research Mesoblast Ltd (MESO) on Bullrun: market cap USD 1.83B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMESO
- ExchangeNASDAQ
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.83B
- Financial periodFY2026
- RevenueUSD 120.25M
- Revenue growth599.2%
- Net income-USD 57.50M
- Free cash flow-USD 44.73M
- Gross margin86.1%
Valuation Snapshot
latest market cap is USD 1.83B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | USD 120.25M | -USD 57.50M | -USD 44.73M | 86.1% | n/a | USD 47.39M | USD 127.33M | USD 568.41M |
| FY2025 | USD 17.20M | -USD 102.14M | -USD 50.68M | 70.2% | -0.85 | USD 161.16M | USD 128.16M | USD 597.44M |
| FY2024 | USD 5.90M | -USD 87.96M | -USD 48.79M | 100.0% | -0.89 | USD 62.56M | USD 118.92M | USD 480.36M |
| FY2023 | USD 7.50M | -USD 81.89M | -USD 63.58M | 100.0% | -1.05 | USD 70.92M | USD 116.50M | USD 501.84M |
| FY2022 | USD 10.21M | -USD 91.35M | -USD 66.01M | n/a | -133.8 | USD 60.03M | USD 106.91M | USD 497.04M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 1.83B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.31B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.28B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 188.79M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 452.13M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 656.26M | n/a | n/a | n/a |
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Related stock research
Other Healthcare stocks
Adalta Ltd (1AD)
Algorae Pharmaceuticals Ltd (1AI)
Acrux Limited (ACR.AX)
Actinogen Medical Ltd (ACW)
Argenica Therapeutics Ltd (AGN)
Anatara Lifesciences Ltd (ANR)
Alterity Therapeutics Ltd (ATHE)
Avecho Biotechnology Limited (AVE.AX)
Botanix Pharmaceuticals Ltd (BOT)
Chimeric Therapeutics Ltd (CHM)
Cambium Bio Ltd (CMB)
Cynata Therapeutics Ltd (CYP)
Frequently asked questions
What is Mesoblast Ltd's market cap?
Mesoblast Ltd's market capitalization is USD 1.83B.
What does Mesoblast Ltd do?
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.